Chimerix Regains Worldwide Rights To CMX157 From Merck - Quick Facts

(RTTNews) - Chimerix Inc. (CMRX) announced that it has regained the worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate, from Merck, known as MSD outside the United States and Canada.

Following a routine pipeline portfolio assessment, Merck made the decision to no longer pursue development of CMX157.

The compound is currently being evaluated for future development opportunities; however, Chimerix has no present plans for allocation of current or future resources to the development of CMX157.

CMX157 is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. CMX157 is active against HBV and more than 200-fold more potent in vitro versus tenofovir against all major HIV subtypes resistant to current therapies, which may allow activity against tenofovir-resistant viruses (e.g., K65R).